Verastem, Inc. Files 8-K on Officer/Director Changes
Ticker: VSTM · Form: 8-K · Filed: Dec 19, 2025 · CIK: 1526119
| Field | Detail |
|---|---|
| Company | Verastem, INC. (VSTM) |
| Form Type | 8-K |
| Filed Date | Dec 19, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: officer-changes, director-changes, regulation-fd
TL;DR
Verastem leadership shakeup: new officers/directors appointed, check the details.
AI Summary
Verastem, Inc. filed an 8-K on December 19, 2025, reporting events as of December 15, 2025. The filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. It also includes Regulation FD disclosures and financial statements/exhibits.
Why It Matters
This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational oversight.
Risk Assessment
Risk Level: medium — Changes in directors or officers can signal underlying issues or strategic shifts that may affect the company's future performance.
Key Players & Entities
- Verastem, Inc. (company) — Registrant
- December 15, 2025 (date) — Earliest event reported
- December 19, 2025 (date) — Filing date
- Needham, MA (location) — Principal Executive Offices
FAQ
What specific officer or director positions were affected by the events reported on December 15, 2025?
The filing indicates "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers" but does not specify the names or exact roles in the provided text.
Are there any details regarding the compensatory arrangements for the newly appointed officers?
The filing lists "Compensatory Arrangements of Certain Officers" as an item, but the specific details of these arrangements are not included in the provided text.
What is the significance of the "Regulation FD Disclosure" mentioned in the filing?
Regulation FD (Fair Disclosure) ensures that material non-public information is disclosed to all investors simultaneously, suggesting that important company information may have been shared publicly.
What are the primary business activities of Verastem, Inc. based on its SIC code?
Verastem, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Where are Verastem, Inc.'s principal executive offices located?
Verastem, Inc.'s principal executive offices are located at 117 Kendrick Street, Suite 500, Needham, MA 02494.
Filing Stats: 685 words · 3 min read · ~2 pages · Grade level 11.4 · Accepted 2025-12-19 17:21:51
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share VSTM The Nasdaq
Filing Documents
- tm2533463d1_8k.htm (8-K) — 27KB
- tm2533463d1_ex10-1.htm (EX-10.1) — 44KB
- tm2533463d1_ex99-1.htm (EX-99.1) — 30KB
- tm2533463d1_ex10-1img001.jpg (GRAPHIC) — 4KB
- 0001104659-25-123295.txt ( ) — 291KB
- vstm-20251215.xsd (EX-101.SCH) — 3KB
- vstm-20251215_lab.xml (EX-101.LAB) — 33KB
- vstm-20251215_pre.xml (EX-101.PRE) — 22KB
- tm2533463d1_8k_htm.xml (XML) — 4KB
02. Departure of Directors or Certain
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Departure of Chief Operating Officer As previously disclosed on December 15, 2025, as of December 19, 2025, Matthew Ros separated from Verastem, Inc. (the "Company") as its Chief Operating Officer. In connection with his separation, on December 19, 2025, the Company entered into a Separation Agreement (the "Separation Agreement") with Mr. Ros. Under the Separation Agreement, Mr. Ros will receive severance benefits consistent with his employment agreement with the Company, dated January 14, 2025. These benefits include (i) nine months of base salary continuation, (ii) if Mr. Ros exercises his right to continue participation in the Company's health and dental plans under the federal law known as COBRA, a monthly cash amount equal to the full premium cost of that participation for nine months (or, if earlier, until the time when Mr. Ros becomes eligible to enroll in the health or dental plan of a new employer) and (iii) a pro-rated bonus payment for the portion of the year during which Mr. Ros was employed by the Company prior to the separation, with the actual amount of any bonus determined by actual performance of the Company. The Separation Agreement includes customary provisions regarding release of claims, non-disparagement, cooperation and return of Company property. The foregoing summary of the Separation Agreement is qualified in its entirety by the copy of the Separation Agreement filed as Exhibit 10.1 hereto and incorporated herein by this reference.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On December 15, 2025, the Company issued a press release announcing, among other developments, Mr. Ros's departure. A copy of this press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K. Item 9.01. Financial Statements and Exhibits Exhibit No. Description 10.1 Separation Agreement dated December 19, 2025 by and between Verastem, Inc. and Matthew Ros 99.1 Press Release, dated December 15, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERASTEM, INC. Dated: December 19, 2025 By: /s/ Daniel W. Paterson Daniel W. Paterson President and Chief Executive Officer